New technologies for influenza vaccines

Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1

(2013) P. D. Kwong et al.   Cold Spring Harbor Perspectives in Medicine

Pathogenesis of Influenza A/H5N1 Virus Infection in Ferrets Differs between Intranasal and Intratracheal Routes of Inoculation

(2011) Rogier Bodewes et al.   AMERICAN JOURNAL OF PATHOLOGY

Microneedle Vaccination with Stabilized Recombinant Influenza Virus Hemagglutinin Induces Improved Protective Immunity

(2011) William C. Weldon et al.   Clinical and Vaccine Immunology

Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement

(2011) Filippo Ansaldi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference

(2011) Allyn Bandell et al.   Expert Review of Vaccines

H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy

(2011) J.-F. Rahier et al.   GUT

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

(2011) Jens Wrammert et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Avian glycan-specific IgM monoclonal antibodies for the detection and quantitation of type A and B haemagglutinins in egg-derived influenza vaccines

(2011) Isabelle Legastelois et al.   JOURNAL OF VIROLOGICAL METHODS

H5N1 Virus-Like Particle Vaccine Elicits Cross-Reactive Neutralizing Antibodies That Preferentially Bind to the Oligomeric Form of Influenza Virus Hemagglutinin in Humans

(2011) S. Khurana et al.   JOURNAL OF VIROLOGY

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

(2011) Julie E Ledgerwood et al.   LANCET INFECTIOUS DISEASES

Optimizing the baculovirus expression vector system

(2011) Richard B. Hitchman et al.   METHODS

Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children

(2011) Timo Vesikari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity and Efficacy of Flagellin-Fused Vaccine Candidates Targeting 2009 Pandemic H1N1 Influenza in Mice

(2011) Ge Liu et al.   PLoS One

Adenovirus-Vectored Drug-Vaccine Duo as a Rapid-Response Tool for Conferring Seamless Protection against Influenza

(2011) Jianfeng Zhang et al.   PLoS One

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin

(2011) J. R. R. Whittle et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

(2011) Theodore F. Tsai et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins

(2011) D. Corti et al.   SCIENCE

A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses

(2011) D. C. Ekiert et al.   SCIENCE

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico

(2011) Constantino López-Macías et al.   VACCINE

Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays

(2011) Barry Lorbetskie et al.   VACCINE

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity

(2011) Sandra Morel et al.   VACCINE

Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125, STF2.HA1 SI)

(2011) David N. Taylor et al.   VACCINE

Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults

(2011) Robert W. Frenck et al.   VACCINE

Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children

(2011) Sara Meier et al.   VACCINE

Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults

(2011) Christine B. Turley et al.   VACCINE

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age☆

(2011) R. Baxter et al.   VACCINE

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial

(2011) John J. Treanor et al.   VACCINE

Trivalent and quadrivalent MF59®-adjuvanted influenza vaccine in young children: A dose- and schedule-finding study

(2011) Giovanni Della Cioppa et al.   VACCINE

Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study

(2010) Pierre Van Damme et al.   BMC INFECTIOUS DISEASES

Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents

(2010) Vincenzo Baldo et al.   Clinical & Developmental Immunology

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

(2010) Paolo Durando et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults

(2010) Christopher S. Ambrose et al.   Influenza and Other Respiratory Viruses

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine

(2010) Davide Corti et al.   JOURNAL OF CLINICAL INVESTIGATION

Needle-free influenza vaccination

(2010) Jean-Pierre Amorij et al.   LANCET INFECTIOUS DISEASES

Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial

(2010) Karl G Nicholson et al.   LANCET INFECTIOUS DISEASES

Dissolving polymer microneedle patches for influenza vaccination

(2010) Sean P Sullivan et al.   NATURE MEDICINE

Comparative Efficacy of Hemagglutinin, Nucleoprotein, and Matrix 2 Protein Gene-Based Vaccination against H5N1 Influenza in Mouse and Ferret

(2010) Srinivas S. Rao et al.   PLoS One

Properly Folded Bacterially Expressed H1N1 Hemagglutinin Globular Head and Ectodomain Vaccines Protect Ferrets against H1N1 Pandemic Influenza Virus

(2010) Surender Khurana et al.   PLoS One

Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza

(2010) Nathalie Landry et al.   PLoS One

Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses

(2010) Andres G. Grandea et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome

(2010) D. G. Gibson et al.   SCIENCE

Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination

(2010) C.-J. Wei et al.   SCIENCE

Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant

(2010) Zhiwei Sui et al.   VACCINE

NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets

(2010) Bin Zhou et al.   VACCINE

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates

(2010) Filippo Ansaldi et al.   VACCINE

The need for quadrivalent vaccine against seasonal influenza

(2010) Robert B. Belshe   VACCINE

Safety and immunogenicity of a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125) in healthy young adults

(2010) John J. Treanor et al.   VACCINE

Structure-based design of NS2 mutants for attenuated influenza A virus vaccines

(2010) Hatice Akarsu et al.   VIRUS RESEARCH

Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus

(2010) Wei Zhang et al.   Protein & Cell

Clinical Implications of Aging Skin

(2009) Miranda A. Farage et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial

(2009) Jiri Beran et al.   BMC Medicine

Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara

(2009) Guus F Rimmelzwaan et al.   Expert Review of Vaccines

Current status and progress of prepandemic and pandemic influenza vaccine development

(2009) Isabel Leroux-Roels et al.   Expert Review of Vaccines

Emulsion-based adjuvants for influenza vaccines

(2009) Frederick R Vogel et al.   Expert Review of Vaccines

Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines

(2009) De-chu C Tang et al.   Expert Review of Vaccines

Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria™) in adult and elderly subjects

(2009) R. Gasparini et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture

(2009) Agnieszka Szymczakiewicz‐Multanowska et al.   JOURNAL OF INFECTIOUS DISEASES

Subunit Influenza Vaccines Produced from Cell Culture or in Embryonated Chicken Eggs: Comparison of Safety, Reactogenicity, and Immunogenicity

(2009) Keith S. Reisinger et al.   JOURNAL OF INFECTIOUS DISEASES

A Cell Culture (Vero)–Derived H5N1 Whole‐Virus Vaccine Induces Cross‐Reactive Memory Responses

(2009) Hartmut J. Ehrlich et al.   JOURNAL OF INFECTIOUS DISEASES

Pre‐ and Postexposure Use of Human Monoclonal Antibody against H5N1 and H1N1 Influenza Virus in Mice: Viable Alternative to Oseltamivir

(2009) Wouter Koudstaal et al.   JOURNAL OF INFECTIOUS DISEASES

A Novel Type of Influenza Vaccine: Safety and Immunogenicity of Replication‐Deficient Influenza Virus Created by Deletion of the Interferon Antagonist NS1

(2009) Volker Wacheck et al.   JOURNAL OF INFECTIOUS DISEASES

A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide

(2009) Changgui Li et al.   Nature Protocols

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

(2009) Jianhua Sui et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Comparative Efficacy of Inactivated and Live Attenuated Influenza Vaccines

(2009) Arnold S. Monto et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine

(2009) Tristan W. Clark et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant

(2009) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults

(2009) Angelika Banzhoff et al.   PLoS One

Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin

(2009) David J. M. Lewis et al.   PLoS One

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody Recognition of a Highly Conserved Influenza Virus Epitope

(2009) D. C. Ekiert et al.   SCIENCE

Human innate immunosenescence: causes and consequences for immunity in old age

(2009) Alexander Panda et al.   TRENDS IN IMMUNOLOGY

Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible

(2009) L.B.S. Gelinck et al.   VACCINE

Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old

(2009) W.A. Keitel et al.   VACCINE

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 months

(2009) James C. King et al.   VACCINE

Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses

(2009) Graeme E. Price et al.   VACCINE

Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation, July 2007, NIBSC, Potters Bar, UK

(2009) Philip D. Minor et al.   VACCINE

A universal epitope-based influenza vaccine and its efficacy against H5N1

(2009) Y. Adar et al.   VACCINE

Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages

(2009) B. Camilloni et al.   VACCINE

A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route

(2009) Shital M. Patel et al.   VACCINE

A novel assay for influenza virus quantification using surface plasmon resonance

(2009) C. Estmer Nilsson et al.   VACCINE

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial

(2009) Wendy Keitel et al.   VACCINE

Cross-Protective Potential of a Novel Monoclonal Antibody Directed against Antigenic Site B of the Hemagglutinin of Influenza A Viruses

(2009) Reiko Yoshida et al.   PLoS Pathogens

Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005)

(2008) Renata J. M. Engler   ARCHIVES OF INTERNAL MEDICINE

Systematic review of worldwide variations of the prevalence of wheezing symptoms in children

(2008) Swatee P Patel et al.   Environmental Health

Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza

(2008) Christopher S. Ambrose et al.   Influenza and Other Respiratory Viruses

An Influenza A Vaccine Based on Tetrameric Ectodomain of Matrix Protein 2

(2008) Marina De Filette et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Prevention of Symptomatic Seasonal Influenza in 2005–2006 by Inactivated and Live Attenuated Vaccines

(2008) Suzanne E. Ohmit et al.   JOURNAL OF INFECTIOUS DISEASES

An Adjuvanted, Low‐Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross‐Reactive Immune Responses in Healthy Adults

(2008) Karin Levie et al.   JOURNAL OF INFECTIOUS DISEASES

Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults

(2008) David I. Bernstein et al.   JOURNAL OF INFECTIOUS DISEASES

Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine after Priming with an Antigenic Variant

(2008) Nega Ali Goji et al.   JOURNAL OF INFECTIOUS DISEASES

Intradermal Influenza Vaccine Administered Using a New Microinjection System Produces Superior Immunogenicity in Elderly Adults: A Randomized Controlled Trial

(2008) David Holland et al.   JOURNAL OF INFECTIOUS DISEASES

The Evolutionary Dynamics of Human Influenza B Virus

(2008) Rubing Chen et al.   JOURNAL OF MOLECULAR EVOLUTION

Live Attenuated Influenza Viruses Containing NS1 Truncations as Vaccine Candidates against H5N1 Highly Pathogenic Avian Influenza

(2008) J. Steel et al.   JOURNAL OF VIROLOGY

Comparative Efficacy of Neutralizing Antibodies Elicited by Recombinant Hemagglutinin Proteins from Avian H5N1 Influenza Virus

(2008) C.-J. Wei et al.   JOURNAL OF VIROLOGY

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial

(2008) Sarah A Frech et al.   LANCET

Structure and mechanism of the M2 proton channel of influenza A virus

(2008) Jason R. Schnell et al.   NATURE

Structural basis for the function and inhibition of an influenza virus proton channel

(2008) Amanda L. Stouffer et al.   NATURE

Antigenically Distinct MF59-Adjuvanted Vaccine to Boost Immunity to H5N1

(2008) Iain Stephenson et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture

(2008) Hartmut J. Ehrlich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influenza virus-like particles produced by transient expression inNicotiana benthamianainduce a protective immune response against a lethal viral challenge in mice

(2008) Marc-André D’Aoust et al.   PLANT BIOTECHNOLOGY JOURNAL

Cross-Clade Protective Immune Responses to Influenza Viruses with H5N1 HA and NA Elicited by an Influenza Virus-Like Particle

(2008) Rick A. Bright et al.   PLoS One

Efficacious Recombinant Influenza Vaccines Produced by High Yield Bacterial Expression: A Solution to Global Pandemic and Seasonal Needs

(2008) Langzhou Song et al.   PLoS One

Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry

(2008) Tracie L. Williams et al.   VACCINE

Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults

(2008) Isabel Leroux-Roels et al.   VACCINE

Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

(2008) Filippo Ansaldi et al.   VACCINE

Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults

(2008) Pierre Van Damme et al.   VACCINE

HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines

(2008) J.C. Kapteyn et al.   VACCINE

Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: A sequential Phase I and Phase II clinical trial

(2008) N. Groth et al.   VACCINE